AGIO Agios Pharmaceuticals, Inc.

+0.22  (0%)
Previous Close 47.24
Open 47.73
Price To book 6.51
Market Cap 2.29B
Shares 48,204,000
Volume 478,820
Short Ratio 13.19
Av. Daily Volume 590,822

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due by end of 2017.
IDH1m Relapsed/Refractory AML - cancer
Phase 2 first data released at EHA meeting June 2016. Updated data due at EHA June 24, 2017 with further data due 2H 2017.
Pyruvate kinase deficiency
Phase 3 to be initiated 2Q 2017.
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of April 2017.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
PDUFA date August 30, 2017 under priority review.
Enasidenib (AG-221)
Advanced hematologic malignancies with an IDH2 mutation
Phase 3 initiated December 2016.
IDH1 mutant positive cholangiocarcinoma - cancer

Latest News

  1. ETFs with exposure to Agios Pharmaceuticals, Inc. : May 22, 2017
  2. A small Boston biotech is at the heart of a groundbreaking approach to tackling cancer
  3. Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHA
  4. Agios to Present New Clinical Data from its IDH Programs at ASCO
  5. Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract
  6. Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AGIO-US : May 15, 2017
  7. Edited Transcript of AGIO earnings conference call or presentation 4-May-17 12:00pm GMT
  8. Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
  9. Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus
  10. Agios Pharmaceuticals reports 1Q loss
  11. Investor Network: Agios Pharmaceuticals, Inc. to Host Earnings Call
  12. Agios Reports First Quarter 2017 Financial Results
  13. 3 Debt-Free Clinical-Stage Biotech Stocks That Are Swimming in Cash
  14. [$$] Four Small Biotechs See Bullish April Stock Buys
  15. Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?
  16. Agios Announces Closing of Over-Allotment Option in Public Offering
  17. Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target
  18. Agios to Webcast Conference Call of First Quarter 2017 Financial Results on May 4, 2017
  19. The 1 Stock I'd Buy Right Now